바이오인

India has already done much to further access to medicines throughout the developing world by producing low-cost generic drugs and follow-on vaccines. As its economy grows and government and industry invest in innovation, many hope India can now contribute in a new way, by developing badly needed new and adapted vaccines, drugs and diagnostics for diseases of the poor. But what is India’s current capacity for new health technology development and how is this capacity likely to evolve? Do the government’s policies support innovation that is important to public health? And as Indian firms gain access to markets in the US and Europe, will they still invest in products for neglected infectious diseases? The Center’s draft study, “India’s Role in Global Health R&D”, sets out to answer these questions.